{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:57:46Z","timestamp":1789016266938,"version":"build-2803163510"},"reference-count":52,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Patients receiving opioid analgesics may experience constipation [ie, opioid-induced constipation (OIC)], require treatment to induce laxation, and may be at risk for gastrointestinal perforation, an uncommon but potentially life-threatening condition. Management of OIC includes treatment with over-the-counter laxatives and peripherally acting \u03bc-opioid receptor antagonists (PAMORAs; methylnaltrexone, naloxegol, naldemedine). In patients receiving treatment for OIC, gastrointestinal perforation may result from the laxation process, causing disruption of the gastrointestinal lining that may already have compromised integrity. A PubMed literature review and a search of the US Food and Drug Administration Adverse Event Reporting System database identified several cases of gastrointestinal perforation (life-threatening or with mortality) across the range of agents administered for the treatment of OIC or other constipation types. Methylnaltrexone in the subcutaneous form was the first PAMORA approved for OIC. Its real-world use in the \u223c6 years before the availability of another OIC-indicated PAMORA helped establish the adverse-event profile of the class, and experience has been gained in identifying and treating appropriate patient populations. Class labeling of PAMORAs includes a contraindication in patients with known or suspected gastrointestinal obstruction or increased risk of recurrent obstruction. Appropriate patient selection during laxation therapy for OIC, regardless of treatment plan, involves consideration of the overall risk versus benefit in patients at increased risk of perforation due to comorbid medical conditions, concurrent medications, or recent gastrointestinal procedures. After initiating treatment for OIC, clinicians should assess the effectiveness of laxation therapy and carefully monitor for signs of gastrointestinal perforation.<\/jats:p>","DOI":"10.1097\/mcg.0000000000002185","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T16:14:50Z","timestamp":1748448890000},"page":"491-496","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Treatment of Opioid-Induced Constipation"],"prefix":"10.1097","volume":"59","author":[{"given":"Neel","family":"Mehta","sequence":"first","affiliation":[{"name":"Weill Cornell Medical College"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam P.","family":"Laitman","sequence":"additional","affiliation":[{"name":"Salix Pharmaceuticals, Bridgewater, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rowe B.","family":"Brookfield","sequence":"additional","affiliation":[{"name":"Salix Pharmaceuticals, Bridgewater, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucinda A.","family":"Harris","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Scottsdale, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,7]]},"reference":[{"key":"R1-20250613","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.mcna.2007.12.004","article-title":"Gastrointestinal perforation and the acute abdomen","volume":"92","author":"Langell","year":"2008","journal-title":"Med Clin North Am"},{"key":"R3-20250613","first-page":"1","article-title":"Rectal perforations caused by cleansing enemas in chronically constipated patients: two case reports","volume":"8","author":"Lee","year":"2020","journal-title":"SAGE Open Med Case Rep"},{"key":"R4-20250613","doi-asserted-by":"crossref","first-page":"695","DOI":"10.3349\/ymj.2011.52.4.695","article-title":"Bowel perforation after erlotinib treatment in a patient with non-small cell lung cancer","volume":"52","author":"Cheon","year":"2011","journal-title":"Yonsei Med J"},{"key":"R5-20250613","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1179\/1973947815Y.0000000053","article-title":"Risk of gastrointestinal perforation in cancer patients receiving ramucirumab: a meta-analysis of randomized controlled trials","volume":"28","author":"Wang","year":"2016","journal-title":"J Chemother"},{"key":"R6-20250613","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13256-018-1619-x","article-title":"Bevacizumab-induced intestinal perforation in a patient with inoperable breast cancer: a case report and review of the literature","volume":"12","author":"Fujii","year":"2018","journal-title":"J Med Case Rep"},{"key":"R7-20250613","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1111\/apt.16601","article-title":"Bevacizumab and gastrointestinal perforations: a review from the FDA Adverse Event Reporting System (FAERS) database","volume":"54","author":"Wichelmann","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"R8-20250613","doi-asserted-by":"crossref","first-page":"e1952","DOI":"10.1002\/cnr2.1952","article-title":"Gastrointestinal perforation associated with bevacizumab in metastatic colorectal cancer","volume":"7","author":"Fang","year":"2024","journal-title":"Cancer Rep (Hoboken)"},{"key":"R9-20250613","doi-asserted-by":"crossref","first-page":"11235","DOI":"10.3389\/jpps.2023.11235","article-title":"Gastrointestinal perforation associated with novel antineoplastic agents: a real-world study based on the FDA Adverse Event Reporting System","volume":"26","author":"Yu","year":"2023","journal-title":"J Pharm Pharm Sci"},{"key":"R10-20250613","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1002\/art.39761","article-title":"Brief report: risk of gastrointestinal perforation among rheumatoid arthritis patients receiving tofacitinib, tocilizumab, or other biologic treatments","volume":"68","author":"Xie","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"R11-20250613","doi-asserted-by":"crossref","first-page":"e001201","DOI":"10.1136\/rmdopen-2020-001201","article-title":"Gastrointestinal perforations in patients with rheumatoid arthritis treated with biological disease-modifying antirheumatic drugs in Sweden: a nationwide cohort study","volume":"6","author":"Barbulescu","year":"2020","journal-title":"RMD Open"},{"key":"R12-20250613","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1002\/acr.21764","article-title":"Factors associated with gastrointestinal perforation in a cohort of patients with rheumatoid arthritis","volume":"64","author":"Curtis","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R13-20250613","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1136\/ard.2003.010355","article-title":"Steroids, non-steroidal anti-inflammatory drugs, and sigmoid diverticular abscess perforation in rheumatic conditions","volume":"63","author":"Mpofu","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"R14-20250613","doi-asserted-by":"crossref","first-page":"e004587","DOI":"10.1136\/bmjopen-2013-004587","article-title":"Corticosteroids and risk of gastrointestinal bleeding: a systematic review and meta-analysis","volume":"4","author":"Narum","year":"2014","journal-title":"BMJ Open"},{"key":"R15-20250613","doi-asserted-by":"crossref","first-page":"57","DOI":"10.5055\/jom.0850","article-title":"Role of opioid use in gastrointestinal obstruction and perforation: a retrospective review","volume":"20","author":"Bishnoi","year":"2024","journal-title":"J Opioid Manag"},{"key":"R16-20250613","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/2050640618818305","article-title":"Pathophysiology and management of opioid-induced constipation: European Expert Consensus Statement","volume":"7","author":"Farmer","year":"2019","journal-title":"United European Gastroenterol J"},{"key":"R17-20250613","doi-asserted-by":"crossref","first-page":"101644","DOI":"10.1016\/j.legalmed.2019.101644","article-title":"Rapid death following undiagnosed stercoral perforation in a chronic opioid user","volume":"42","author":"Heimer","year":"2020","journal-title":"Leg Med (Tokyo)"},{"key":"R18-20250613","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ijscr.2017.11.060","article-title":"Opioid drugs and stercoral perforation of the colon: case report and review of literature","volume":"42","author":"Poitras","year":"2018","journal-title":"Int J Surg Case Rep"},{"key":"R19-20250613","doi-asserted-by":"crossref","first-page":"e54040","DOI":"10.1371\/journal.pone.0054040","article-title":"Morphine induces bacterial translocation in mice by compromising intestinal barrier function in a TLR-dependent manner","volume":"8","author":"Meng","year":"2013","journal-title":"PLoS One"},{"key":"R20-20250613","doi-asserted-by":"crossref","first-page":"a040485","DOI":"10.1101\/cshperspect.a040485","article-title":"Opioid modulation of the gut-brain axis in opioid-associated comorbidities","volume":"11","author":"Zhang","year":"2021","journal-title":"Cold Spring Harb Perspect Med"},{"key":"R21-20250613","doi-asserted-by":"crossref","first-page":"7999","DOI":"10.3390\/ijms25147999","article-title":"Opioid use and gut dysbiosis in cancer pain patients","volume":"25","author":"Coluzzi","year":"2024","journal-title":"Int J Mol Sci"},{"key":"R22-20250613","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.14309\/ajg.0000000000002887","article-title":"Opioids and the gastrointestinal tract: The role of peripherally active micro-opioid receptor antagonists in modulating intestinal permeability","volume":"119","author":"Lacy","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"R23-20250613","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.3748\/wjg.14.4569","article-title":"Diagnosis and treatment of spontaneous colonic perforation: analysis of 10 cases","volume":"14","author":"Yang","year":"2008","journal-title":"World J Gastroenterol"},{"key":"R24-20250613","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S2468-1253(21)00001-7","article-title":"Stercoral perforation due to chronic constipation","volume":"6","author":"Chen","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R25-20250613","first-page":"1","article-title":"Severe constipation causing ischaemic stercoral perforation of sigmoid colon","volume":"3","author":"Zhang","year":"2023","journal-title":"J Surg Case Rep"},{"key":"R26-20250613","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1136\/bmj.284.6314.472","article-title":"Faecal peritonitis after laxative preparation for barium enema","volume":"284","author":"Galloway","year":"1982","journal-title":"Br Med J (Clin Res Ed)"},{"key":"R27-20250613","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jpainsymman.2010.01.011","article-title":"Methylnaltrexone and gastrointestinal perforation","volume":"40","author":"Mackey","year":"2010","journal-title":"J Pain Symptom Manage"},{"key":"R28-20250613","doi-asserted-by":"crossref","first-page":"E471","DOI":"10.1055\/s-0043-106200","article-title":"Retrospective analysis of large bowel obstruction or perforation caused by oral preparation for colonoscopy","volume":"5","author":"Yamauchi","year":"2017","journal-title":"Endosc Int Open"},{"key":"R29-20250613","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/j.1365-2036.2008.03689.x","article-title":"Gastrointestinal side effects in chronic opioid users: results from a population-based survey","volume":"27","author":"Cook","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"R30-20250613","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s40122-022-00392-y","article-title":"A survey of the incidence of constipation in patients with chronic non-cancer pain using opioid analgesics in Japan","volume":"11","author":"Sonohata","year":"2022","journal-title":"Pain Ther"},{"key":"R31-20250613","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1177\/2050640616659967","article-title":"Prevalence and clinical features of opioid-induced constipation in the general population: a French study of 15,000 individuals","volume":"5","author":"Ducrotte","year":"2017","journal-title":"United European Gastroenterol J"},{"key":"R32-20250613","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1007\/s40122-021-00271-y","article-title":"Impact and consequences of opioid-induced constipation: a survey of patients","volume":"10","author":"Varrassi","year":"2021","journal-title":"Pain Ther"},{"key":"R33-20250613","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1007\/s12325-021-01766-y","article-title":"Management of opioid-induced constipation and bowel dysfunction: expert opinion of an Italian multidisciplinary panel","volume":"38","author":"De Giorgio","year":"2021","journal-title":"Adv Ther"},{"key":"R34-20250613","doi-asserted-by":"crossref","first-page":"131","DOI":"10.5056\/jnm23144","article-title":"Opioid-induced constipation: old and new concepts in diagnosis and treatment","volume":"30","author":"Squeo","year":"2024","journal-title":"J Neurogastroenterol Motil"},{"key":"R35-20250613","doi-asserted-by":"crossref","first-page":"e14574","DOI":"10.1111\/nmo.14574","article-title":"The national prevalence of disorders of gut brain interaction in the United Kingdom in comparison to their worldwide prevalence: results from the Rome foundation global epidemiology study","volume":"35","author":"Jaafari","year":"2023","journal-title":"Neurogastroenterol Motil"},{"key":"R36-20250613","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.regpep.2009.03.012","article-title":"Opioid receptors in the gastrointestinal tract","volume":"155","author":"Holzer","year":"2009","journal-title":"Regul Pept"},{"key":"R37-20250613","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1053\/j.gastro.2018.07.016","article-title":"American Gastroenterological Association Institute guideline on the medical management of opioid-induced constipation","volume":"156","author":"Crockett","year":"2019","journal-title":"Gastroenterology"},{"key":"R38-20250613","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/j.cgh.2017.05.014","article-title":"Opioids in gastroenterology: treating adverse effects and creating therapeutic benefits","volume":"15","author":"Camilleri","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R39-20250613","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/ajgsup.2014.7","article-title":"Opioid-induced bowel dysfunction: epidemiology, pathophysiology, diagnosis, and initial therapeutic approach","volume":"2","author":"Dorn","year":"2014","journal-title":"Am J Gastroenterol Suppl"},{"key":"R40-20250613","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12904-020-00693-z","article-title":"Delphi consensus on strategies in the management of opioid-induced constipation in cancer patients","volume":"20","author":"Sarri\u00f3","year":"2021","journal-title":"BMC Palliat Care"},{"key":"R45-20250613","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/MCG.0000000000001801","article-title":"Management of opioid-induced constipation in older adults","volume":"57","author":"Horrigan","year":"2023","journal-title":"J Clin Gastroenterol"},{"key":"R46-20250613","doi-asserted-by":"crossref","first-page":"9625","DOI":"10.1038\/s41598-019-44864-2","article-title":"Methylnaltrexone is safe in cancer patients with peritoneal carcinomatosis","volume":"9","author":"Nelson","year":"2019","journal-title":"Sci Rep"},{"key":"R47-20250613","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1213\/XAA.0000000000000840","article-title":"Methylnaltrexone-associated bowel perforation in postoperative opioid-induced constipation and Ogilvie syndrome: a case report","volume":"12","author":"Blackney","year":"2019","journal-title":"A A Pract"},{"key":"R48-20250613","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40780-024-00371-9","article-title":"Naldemedine-induced perforation of a diverticulum in the sigmoid colon of a patient with opioid-related constipation: a case report","volume":"10","author":"Yokota","year":"2024","journal-title":"J Pharm Health Care Sci"},{"key":"R49-20250613","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jpainsymman.2007.12.005","article-title":"Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study","volume":"35","author":"Portenoy","year":"2008","journal-title":"J Pain Symptom Manage"},{"key":"R50-20250613","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1056\/NEJMoa0707377","article-title":"Methylnaltrexone for opioid-induced constipation in advanced illness","volume":"358","author":"Thomas","year":"2008","journal-title":"N Engl J Med"},{"key":"R51-20250613","first-page":"39","article-title":"Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients","volume":"7","author":"Slatkin","year":"2009","journal-title":"J Support Oncol"},{"key":"R52-20250613","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1080\/17474124.2019.1575203","article-title":"Safety and tolerability of linaclotide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: pooled Phase 3 analysis","volume":"13","author":"Nee","year":"2019","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"R53-20250613","doi-asserted-by":"crossref","first-page":"920","DOI":"10.3109\/00365529709011203","article-title":"Stool form scale as a useful guide to intestinal transit time","volume":"32","author":"Lewis","year":"1997","journal-title":"Scand J Gastroenterol"},{"key":"R54-20250613","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3111\/13696990903430481","article-title":"Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation","volume":"12","author":"Rentz","year":"2009","journal-title":"J Med Econ"},{"key":"R55-20250613","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s40122-020-00195-z","article-title":"What to do and what not to do in the management of opioid-induced constipation: a choosing wisely report","volume":"9","author":"Alvaro","year":"2020","journal-title":"Pain Ther"},{"key":"R56-20250613","first-page":"362","article-title":"Intestinal obstruction: evaluation and management","volume":"98","author":"Jackson","year":"2018","journal-title":"Am Fam Physician"},{"key":"R57-20250613","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13017-019-0240-7","article-title":"Bowel obstruction: a narrative review for all physicians","volume":"14","author":"Catena","year":"2019","journal-title":"World J Emerg Surg"}],"container-title":["Journal of Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCG.0000000000002185","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T12:03:29Z","timestamp":1749816209000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MCG.0000000000002185"}},"subtitle":["Inducing Laxation and Understanding the Risk of Gastrointestinal Perforation"],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":52,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/mcg.0000000000002185","relation":{},"ISSN":["1539-2031"],"issn-type":[{"value":"1539-2031","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,22]]}}}